Kaplan N M
University of Texas Southwestern Medical Center, Dallas 75235-8899, USA.
J Hypertens Suppl. 1998 Jan;16(1):S35-7.
Obesity is becoming an increasingly important factor in the pathogenesis of hypertension, dyslipidemia and diabetes, which together with hyperinsulinemia comprise the deadly quartet of the insulin resistance syndrome. Obesity in the absence of these other factors is only a minor risk factor, but most obesity is accompanied by one or more of these, worsening the prognosis. The presence of obesity complicates the management of hypertension, probably in large part because of the concomitant insulin resistance which adds to the pathogenetic mechanisms and subtracts from the therapeutic efficacy of many antihypertensive regimens. Unfortunately, some of the agents used to reduce obesity may further aggravate the problem through their stimulation of sympathetic nervous activity. Nonetheless, in the treatment of hypertension in most obese patients who have relatively little excess risk, attempts to reduce body weight should be attempted first, through sensible dietary restrictions, increased aerobic exercise and judicious use of non-hypertensinogenic appetite suppressants. Thereby, additional motivation to lose weight may be provided by the potential of escaping or at least delaying antihypertensive drug therapy. TREATMENT OF HIGHER-RISK OBESE INDIVIDUALS: Those obese hypertensive individuals at greater risk should be immediately started on antihypertensive drug therapy along with attempts to reduce the obesity. The choice of initial and subsequent therapy should take the patient's individual needs into account. For those with dyslipidemia or diabetes, diuretics and beta-blockers should be avoided unless there are specific indications for their use (e.g. reactive sodium retention or postmyocardial infarction). In such patients, an alpha-blocker, an angiotensin converting enzyme inhibitor or a calcium antagonist may be more appropriate. If the first drug is not sufficient, combination therapy should be considered. A diuretic may be needed to overcome reactive sodium retention. Because most obese hypertensive individuals will not be able to lose much weight, effective antihypertensive drug therapy will usually be indicated.
肥胖正日益成为高血压、血脂异常和糖尿病发病机制中的一个重要因素,这些疾病与高胰岛素血症共同构成了胰岛素抵抗综合征的致命四重奏。在没有其他这些因素的情况下,肥胖只是一个次要风险因素,但大多数肥胖伴有其中一种或多种因素,会使预后恶化。肥胖的存在使高血压的管理变得复杂,这可能在很大程度上是因为伴随的胰岛素抵抗增加了发病机制,同时降低了许多抗高血压方案的治疗效果。不幸的是,一些用于减轻肥胖的药物可能会通过刺激交感神经活动进一步加剧问题。尽管如此,在治疗大多数额外风险相对较小的肥胖患者的高血压时,应首先尝试通过合理的饮食限制、增加有氧运动和明智地使用非致高血压的食欲抑制剂来减轻体重。由此,减轻体重的额外动力可能来自于避免或至少推迟抗高血压药物治疗的可能性。
那些风险更高的肥胖高血压个体应立即开始抗高血压药物治疗,同时尝试减轻肥胖。初始治疗和后续治疗的选择应考虑患者的个体需求。对于患有血脂异常或糖尿病的患者,应避免使用利尿剂和β受体阻滞剂,除非有特定的使用指征(例如反应性钠潴留或心肌梗死后)。在这类患者中,α受体阻滞剂、血管紧张素转换酶抑制剂或钙拮抗剂可能更合适。如果第一种药物不足,应考虑联合治疗。可能需要使用利尿剂来克服反应性钠潴留。由于大多数肥胖高血压个体无法减轻太多体重,通常需要有效的抗高血压药物治疗。